Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neuvision Development LLC has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit. The concentration of the portfolio suggests a highly specific technical focus for the company's current patenting efforts. The alignment of 1 examiner across 1 art unit for this action provides a very clear view of the company's current legal standing.
The busiest examiner for this portfolio is VIGIL, TORIANA NICHOLE, who is responsible for 1 busiest examiner pending action. Because the total number of pending actions is 1, this examiner handles the entirety of the company's active prosecution before the office. Practitioners should note that the prosecution strategy is currently centralized under a single individual. The lack of variety in examiners and art units suggests a streamlined but singular point of contact with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIGIL, TORIANA NICHOLE | 1 | 52.9% | +26.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18865673 | TOPICAL OCULAR ADMINISTRATION OF AMBROXOL FOR OCULAR PAIN | VIGIL, TORIANA NICHOLE | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18865673 | TOPICAL OCULAR ADMINISTRATION OF AMBROXOL FOR OCULAR PAIN | VIGIL, TORIANA NICHOLE | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Nov 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeuvision Development LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Toriana Nichole Vigil has the most, with 1 of Neuvision Development LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
